Effects of Yisui Jiedu Recipe on JAK2-STAT5 signal transduction pathway in bone marrow hematopoietic cells from patients with myelodysplastic syndrome-refractory anemia

Journal of Chinese Integrative Medicine

Volumn 6, Issue 2, 2008, Pages 185-189

  Tian, Sheng Li ^a   Zhou, Yong Ming ^a   Huang, Tao ^a   Xue, Zhi Zhong ^a   He, Wei ^a  

^a SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

Composite (traditional compound drug); Cytokines; Myelodysplastic syndromes; Signal transduction

Indexed keywords

CHINESE DRUG; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; INTERLEUKIN 3; JANUS KINASE 2; MESSENGER RNA; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; PROTEIN BCL XL; STAT5 PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; YISUI JIEDU;

ARTICLE; BONE MARROW CULTURE; CONTROLLED STUDY; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; MYELODYSPLASTIC SYNDROME; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REFRACTORY ANEMIA; SIGNAL TRANSDUCTION;

ADULT; AGED; ANEMIA, REFRACTORY; BONE MARROW CELLS; CELLS, CULTURED; DRUGS, CHINESE HERBAL; FEMALE; HEMATOPOIESIS; HUMANS; JANUS KINASE 2; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; RNA, MESSENGER; SIGNAL TRANSDUCTION; STAT5 TRANSCRIPTION FACTOR; TYRPHOSTINS;

EID: 39149140723     PISSN: 16721977     EISSN: None     Source Type: Journal    
DOI: 10.3736/jcim20080216     Document Type: Article

References (12)

1. Coffer PJ, Koenderman L, de Groot RP. The role of STATs in myeloid differentiation and leukemia. Oncogene. 2000; 19(21): 2511-2522.
2. Spiekermann K, Biethahn S, Wilde S, et al. Constitutive activation of STAT transcription factors in acute myelogenous leukemia. Eur J Haematol. 2001; 67(2): 63-71.
3. Zhang ZN. Diagnostic and effect evaluation standards of hematology. 2nd ed. Beijing: Science Press. 1998: 263-295.
4. Steelman LS, Pohnert SC, Shelton JG, et al. JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia. 2004; 18(2): 189-218.
5. Kochendoerfer SK, Krishnan N, Buckley DJ, et al. Prolactin regulation of Bcl-2 family members: increased expression of bcl-xL but not mcl-1 or bad in Nb2-T cells. J Endocrinol. 2003; 178(2): 265-273.
6. ++ cells in patients with myelodysplastic syndrome (MDS) and MDS-acute myeloid leukaemia. Br J Haematol. 2003; 121(1): 63-75.
7. Ihle JN. Signaling by the cytokine receptor superfamily in normal and transformed hematopoietic cells. Adv Cancer Res. 1996; 68(1): 23-65.
8. Tian SL. Experience of treatment of myelodysplastic syndrome by Zhou Yongming. Zhong Yi Za Zhi. 2005; 46(1): 14-15.
9. Tian SL, Zhou YM, Ho MH, et al. Treatment of myelodysplastic syndrome by improved prescription of Shengxue Heji: A clinical observation of 60 cases. Xin Zhong Yi. 2005; 37(3): 22-24.
10. Tian SL, Huang T, Zhou YM, et al. Effects of "Yisui Integrative Decoction" on IL-3 and IFN-γ of MDS-RA marrow system. Shanghai Zhong Yi Yao Za Zhi. 2005; 39(2): 26-28.
11. Wang KM, Wang B, He DL. Current status of research on JAK/STAT pathway blocker AG490. Xian Dai Mi Niao Wai Ke Za Zhi. 2003; 8(1): 57-59.
12. Tian SL, Zhou YM, Ge L, et al. The effect of AG490 on JAK2/STAT5 signal transduction pathway in bone marrow hematopoietic cells of MDS-RA. Jian Yan Yi Xue. 2006; 21(3): 278-280.